Literature DB >> 10679722

Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha.

M N Meriggioli1, J Rowin.   

Abstract

Treatment with interferon-alpha (IFN-alpha) has been associated with the occurrence of a number of autoimmune disorders. We report a case of chronic inflammatory demyelinating polyneuropathy (CIDP) occurring in a patient with a chronic viral hepatitis C infection who received a novel, long-acting form of IFN-alpha. After withdrawal of the interferon treatment, this patient responded to a single extended course of plasma exchange that resulted in a complete clinical remission of symptoms without relapse. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10679722     DOI： 10.1002/(sici)1097-4598(200003)23:3<433::aid-mus17>3.0.co;2-o

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


  19 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

2.  Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy.

Authors:  Giovanni Pavesi; Luigi Cattaneo; Adriana Marbini; Franco Gemignani; Domenico Mancia
Journal:  J Neurol       Date:  2002-06       Impact factor: 4.849

3.  Side effects of interferon-alpha therapy.

Authors:  Stefan Sleijfer; Marjolein Bannink; Arthur R Van Gool; Wim H J Kruit; Gerrit Stoter
Journal:  Pharm World Sci       Date:  2005-12

Review 4.  Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Mohamed Mahdi-Rogers; Ruth Brassington; Angela A Gunn; Pieter A van Doorn; Richard Ac Hughes
Journal:  Cochrane Database Syst Rev       Date:  2017-05-08

Review 5.  Inflammatory neuropathies: an update on evaluation and treatment.

Authors:  Lisa D Hobson-Webb; Peter D Donofrio
Journal:  Curr Rheumatol Rep       Date:  2005-10       Impact factor: 4.592

6.  Screening for Electrophysiological Abnormalities in Chronic Hepatitis C Infection: Peripheral Neuropathy and Optic Neuropathy.

Authors:  Aslı Köşkderelioğlu; Pınar Ortan; Alpay Ari; Muhteşem Gedizlioğlu
Journal:  Noro Psikiyatr Ars       Date:  2016-03-01       Impact factor: 1.339

7.  Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C.

Authors:  Kazuaki Nishio; Takeshi Konndo; Shunichi Okada; Machiko Enchi
Journal:  World J Hepatol       Date:  2010-09-27

8.  Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report.

Authors:  Mumtaz A Niazi; Ashaur Azhar; Kashif Tufail; Eyob L Feyssa; Stephen F Penny; Marlene McGregory; Victor Araya; Jorge A Ortiz
Journal:  World J Hepatol       Date:  2010-04-27

Review 9.  Newer therapeutic options for chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Krista Kuitwaard; Pieter A van Doorn
Journal:  Drugs       Date:  2009-05-29       Impact factor: 9.546

Review 10.  Hepatitis C virus and neurological damage.

Authors:  Shilu Mathew; Muhammed Faheem; Sara M Ibrahim; Waqas Iqbal; Bisma Rauff; Kaneez Fatima; Ishtiaq Qadri
Journal:  World J Hepatol       Date:  2016-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.